title: Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
abstract: Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells, which resulted in long-term survival of preclinical xenografts models.
authors: Stem Cells & Cancer Group; Clinical Research Programme; Spanish National Cancer Research Centre (CNIO); Madrid, Spain.
authors: Michele
authors: M
authors: Cioffi
authors: Christopher
authors: C
authors: Heeschen